Logo
Data Snapshot

Search Results

Searched: in measures.


Pathway Title Description Sources Keywords
COVID-19-Briefing-note-40-January-27-2021-vF.pdf?shouldIndex=f

Risk Practice COVID-19 and the great reset: Briefing note #40, January 27, 2021 Vaccine rollout has run into problems. Our new research explores where and why. January 2021 Eugene Mymrin/Getty Images McKinsey research intently continues to examine the progress of SARS-CoV-2 vaccine development and distribution. Last week, we updated our series on the end of the pandemic to consider the emergence of new strains of the virus and a slow start to vaccine rollout. Both represent serious threats to th McKinsey , critical risk areas , risk practice , critical risk , vaccine , risk areas , emergent threat , risk , critical , operating path , path , data path cdc vaccine , vaccine operating path , patient , practice , january , mckinsey , emergent , climate , vaccine administration management system , briefi 31-Jan-2021 auto-generated
The-risks-and-challenges-of-the-global-COVID-19-vaccine-rollout-vF.pdf?shouldIndex=f

Risk Practice The risks and challenges of the global COVID-19- vaccine rollout A realistic assessment of the heroic effort to administer billions of doses of COVID-19 vaccines to an agonized global population is necessary the stakes could not be higher. This article was a collaborative effort by the global Risk Practice and authors from across the firm, including Gaurav Agrawal, Tara Azimi, Jennifer Heller, Pooja Kumar, Mihir Mysore, Parag Patel, Adam Sabow, Shubham Singhal, and Joseph Truesdale McKinsey , vaccines to an agonized , vaccine , united states , vaccines , risks , doses , challenges , vaccine doses , global , critical risk areas , risk , centers for disease control , administration , states , vaccine deployment , united , critical risk , manufacturers , production , risk areas , disease 31-Jan-2021 auto-generated